ISRIB A15 vs Noopept: A Chemist's Honest Comparison

I've been watching Noopept discussions in nootropic communities for years. It's one of those compounds that keeps circulating — people try it, some notice something subtle, most don't notice much at all, and the cycle repeats. There's a r/Nootropics thread from around 2017 that still shows up in searches where someone documented 6 weeks of daily Noopept use and concluded, carefully, that it might be "slightly working." That thread has 400+ comments. Most of them are people asking if they need to cycle it differently.

I bring this up not to dismiss Noopept — it's a real compound with real pharmacology. I bring it up because it illustrates something important about where we are with cognitive enhancement right now: there's a massive gap between what people want (clear, reliable cognitive improvement) and what most compounds actually deliver (modest effects that are hard to distinguish from placebo at the individual level).

ISRIB A15 sits in a different part of the landscape. Not because the marketing says so — because the mechanism is genuinely different. And mechanism matters more than most people realize when they're comparing nootropics.

What Noopept actually does

Noopept is a synthetic dipeptide — technically a prodrug that metabolizes into cycloprolylglycine (CPG), which has some overlap with racetam pharmacology. The proposed mechanisms include AMPA receptor potentiation, increased NGF and BDNF expression, and some modulation of acetylcholine signaling.

The clinical picture is murkier. Most of the published human data on Noopept comes from Russian clinical trials, conducted in the 1990s and 2000s, typically in patients with cognitive impairment from vascular or organic causes. The results in those populations showed modest improvements on cognitive batteries. In healthy young adults — the primary nootropic use case — the picture is far less clear, and most effects, where they exist, are subtle.

The bioavailability story is interesting. Noopept is rapidly absorbed and crosses the blood-brain barrier quickly, which is genuinely good pharmacokinetics for an orally dosed compound. Half-life is short — roughly 15-20 minutes in circulation, though central effects likely persist longer due to receptor binding. This is part of why dosing protocols vary so widely in community discussions: nobody's quite sure if they're taking too much, too little, or whether they'd notice the difference either way.

I'm not dismissing the compound. I'm just being honest about the evidence base.

What ISRIB A15 does, and why the difference matters

ISRIB A15 works upstream of neurotransmitter systems. It targets eIF2B — a protein complex that controls translational activity in cells. When the Integrated Stress Response is chronically active (which happens under conditions of aging, burnout, injury, or sustained psychological stress), eIF2B gets suppressed, and protein synthesis in neurons falls. New proteins are what you need to consolidate long-term memories. No protein synthesis, no memory consolidation. Simple as that.

A15 binds to eIF2B and stabilizes its active conformation. The ISR's brake on cognition gets released. Neurons can make the proteins they need again.

This isn't a neurotransmitter tweak. It's not "more acetylcholine, better recall." It's restoring the cellular machinery that underlies memory formation in the first place. That's a fundamentally different intervention target, which is why the animal data looks so different from what you see with racetam-class compounds.

The Krukowski 2020 paper in eLife showed old mice performing on spatial memory tasks like young mice after ISRIB treatment. Not "somewhat better." Indistinguishably young. Earlier work from the Walter lab — the 2017 paper on TBI — showed memory restoration in brain-injured mice even when dosing started months after injury. These aren't improvements on a continuous scale. They're categorical changes that required a compound acting at the level of protein synthesis regulation.

Noopept doesn't have anything close to this in its data. Neither does piracetam. Neither, frankly, does modafinil — though modafinil has other things going for it.

The solubility thing is worth mentioning

Original ISRIB has terrible aqueous solubility. If you've tried to work with the parent compound, you know what I mean — it dissolves cleanly in DMSO but behaves poorly in water, which creates practical problems for oral dosing when you're working at microgram quantities.

The dichlorophenoxy substitution in A15 changes this meaningfully. The structural modification alters how the molecule sits at the eIF2B binding interface and also improves the practical pharmacokinetics for oral use. This isn't cosmetic chemistry. The analog exists for real reasons.

Noopept doesn't have this problem — it's water-soluble and straightforward to dose. But that's also part of why the dosing discussions are chaotic: people are taking 10mg, 30mg, 80mg, sublingual, intranasal, and reporting wildly variable experiences. The compound is easy to administer, which creates a false sense of precision about what an "effective dose" looks like.

What users actually report

The honest version: Noopept reports vary enormously. Some people notice a kind of verbal fluency or mild mood lift, especially early in a cycle. Others notice nothing. A minority report headaches, irritability, or sleep disruption at higher doses. The LongeCity Noopept threads are informative here — there are years of logs, and the effect profile that emerges is inconsistent.

ISRIB A15 reports are more consistent in character, though not in timing. The memory effect was the first thing I noticed in early community reports — and it kept showing up consistently enough that I stopped dismissing it. Users describe it as a qualitative change in how information feels during learning: easier to retain, easier to retrieve, less effort required to hold things in working memory simultaneously. The clarity effect comes second. Some people feel it within a few days. Others report a slower build over a week. A minority notice nothing immediately and then have a session where something clicks.

Compare that to a representative Noopept report: "I think it might be helping with word recall, hard to tell, going to continue for another month." These are genuinely different effect signatures.

On the mechanism question and what it means for different users

Here's where it gets nuanced.

Noopept's effects — to the extent they exist — likely depend on your baseline cholinergic tone and glutamatergic signaling. If you're acetylcholine-deficient in some functional sense, Noopept might do more for you. If you're not, the effect ceiling is low regardless of dose.

ISRIB A15's effect depends on how active your Integrated Stress Response is. If your ISR is chronically elevated — which is likely if you've had significant burnout, sustained high stress, aging past 35-40, or any kind of prior neurological injury — A15 has more to work with. The brake it releases was actually engaged.

This is probably why the reported responder rates differ. In a healthy 22-year-old with no stress history and good sleep, ISRIB A15 might do less than in a 38-year-old who's been running on fumes for two years. Not because the compound doesn't work, but because there's less ISR-mediated suppression to reverse.

For the typical person seeking cognitive enhancement in 2025 — who has real work demands, real stress accumulation, possibly some burnout history — the ISR angle is more relevant than they might initially assume.

On safety

Noopept has a reasonable safety profile based on years of community use. Short-term, most people tolerate it well. Long-term data in healthy humans is thin — it exists primarily as a commercial product marketed in Russia with limited independent research.

ISRIB A15 is newer in terms of human use. What exists: extensive animal data showing no toxicity at effective doses, no organ damage, no behavioral issues outside of improved cognition. Peter Walter's lab characterized the compound as "completely non-toxic" in their animal work. Human community reports don't flag serious adverse events. But this is still a research compound, 3-4 years of biohacker use at most. I'm not going to pretend that's equivalent to 20 years of modafinil data.

Start at 5mg with A15. Some people find this is the right dose. Some need 10mg. 20mg is on the high end of what I'd suggest before you know how you respond personally. The compound is potent — "more potent" here isn't marketing language, it's a structural consequence of the dichlorophenoxy substitution that affects binding affinity.

The honest comparison

The real question isn't "which one is better" in the abstract. It's: what problem are you actually trying to solve, and which mechanism addresses that problem?

If you want something fast-acting that might provide a subtle lift in verbal fluency for a few hours, Noopept is accessible and cheap. If you're dealing with sustained cognitive underperformance — the kind that comes from stress accumulation, burnout, or simply not feeling like you're operating at the level you know you're capable of — ISRIB A15 is targeting a different and probably more relevant mechanism.

I've watched people cycle through racetams, Noopept, various peptides for years without finding what they were actually looking for. The frustration is real and it's valid. The ISR pathway isn't a new marketing angle — it's the mechanism that explains why the brain gets "stuck" in ways that don't respond to neurotransmitter-level interventions.

That's the distinction worth understanding.